KaloBios Pharmaceuticals Files For IPO

South San Francisco-based KaloBios Pharmaceuticals has filed for an IPO, saying that it is looking to raised $60M on the NASDAQ Global Market as KBIO. The firm's IPO is being underwritten by Leerink Swann, William Blair, and Needham & Company. KaloBios is venture backed by MPM BioVentures, Sofinnova ventures, Alloy Ventures, Fidelity Investments, Lehman Brothers, Baxter International, and GBS Venture Partners. KaloBios is developing monoclonal antibody therapeutics; the firm's lead candidates are aimed at treating pneumonia, severe asthma, and hematologic malignancies.